1. Scrip
  2. >>Business
  3. >>Strategy

If PTAB Backs Berkeley IP Holders' New Patent Claims, CRISPR Licensing Could Be Simplified

 
• By Joseph Haas

The USPTO's PTAB will determine whether UC-Berkeley or Broad Institute holders of CRISPR patents first invented its use in eukaryotic cells. The outcome could either benefit the Berkeley group, which could simplify licensing deals, or maintain the status quo.

INTELLECTUAL PROPERTY Business team hands at work with financial reports and a laptop - Image
IP rights to CRISPR-Cas9 technology again are being investigated by the USPTO

Holders of CRISPR-Cas9 intellectual property affiliated with the University of California, Berkeley (UCB) could gain greater control of those IP rights for use in eukaryotic cell applications under a new interference to be considered by the US Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB), while a finding in favor of Broad Institute IP holders likely would maintain the status quo.

The PTAB announced on 25 June that it will review a potential interference between 10 patent applications by UCB and...

More from Strategy

More from Business

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Xu Hu

Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.

Defying Gravity: Five Drugs That Surpassed Their Sales Forecasts

 
• By Edwin Elmhirst

Many assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.